
Myriad Genetics (NASDAQ:MYGN) Shares Stop Bleeding on Positive Study of Prenatal Genetics Test
It’s certainly been a white-knuckle ride in 2019 for shareholders of the molecular diagnostics and precision medicines company Myriad Genetics (NASDAQ: MYGN), with shares doubling












